As a leader in the biotechnology industry, Clay Siegall, Ph.D., runs a blog where he shares some of the latest news about science and other topics. One recent article described what the oil industry is teaching students in Oklahoma. Teachers from around the state attend the Oklahoma Energy Resource Board where they are taught energy industry-friendly science lessons which they then bring back to their students. The curriculum is funded by the oil industry and is also being used in Kansas and is trying to be advanced in other states.
Another article describes how researchers are hoping to save Lake sturgeon which have been overfished to the point that they might go extinct. This type of fish has been around since the days that dinosaurs walked the earth. In order to help their population recover biologists are hoping to help them breed faster. Some of the materials they are using in this effort includes turkey feathers, clay, and caviar.
Dr. Clay Siegall is the founder of Seattle Genetics, a biotechnology firm headquartered in the suburbs of Seattle, Washington. He founded this company in 1998 and in addition to being its CEO and President he is also the Chairman of the Board. He has years of experience in targeted cancer therapies. These types of therapies, which have been pioneered by Dr. Siegall, are not only more effective than traditional cancer therapies but they are also much safer than practices like chemotherapy and radiation.
Dr. Siegall has forged a number of strategic partnerships in the biotechnology industry which he uses to both collaborate on research but also to sell and market the drugs Seattle Genetics creates. His company specializes in antibody-drug conjugates and his company has over 20 of these ADCs under development. His company has one product on the market ADCETRIC (brentuximab vedotin) which was approved by the FDA in 2011.
As a leader in the industry and acknowledged expert in the field, Dr. Clay Siegall serves on the board of a number of other companies. These companies include Ultragenyx Pharmaceutical, Alder Biopharmaceuticals Inc. and Mirna Therapeutics, Inc.